XNAS
INGN
Market cap160mUSD
Oct 08, Last price
5.94USD
1D
2.06%
1Q
-9.17%
Jan 2017
-91.16%
IPO
-61.05%
Name
Inogen Inc
Chart & performance
P/E
—
P/S
0.46
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.34%
Rev. gr., 5y
2.48%
Revenues
349m
+3.86%
Net income
-23m
L-36.62%
CFO
-11m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
Key people
Scott Wilkinson
President, Chief Executive Officer, Director · since 2017
Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer · since 2014
Bart Sanford
Executive Vice President, Operations · since 2018
Brenton Taylor
Executive Vice President - Engineering · since 2014
Byron Myers
Executive Vice President of Sales and Marketing · since 2017
Benjamin M. Anderson-Ray
Independent Director · since 2013
Scott A. Beardsley
Independent Director · since 2017
Independent Director · since 2015
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
301 Coromar Dr
Goleta, CA 93117
US
Goleta, CA 93117
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||